Literature DB >> 8371715

Kinetic and equilibrium characterization of vesamicol receptor-ligand complexes with picomolar dissociation constants.

G A Rogers1, W D Kornreich, K Hand, S M Parsons.   

Abstract

Previous studies from this laboratory characterized 83 analogs of vesamicol by their potencies for inhibition of acetylcholine active transport by synaptic vesicles isolated from Torpedo electric organ. Examination of the more potent of these compounds, plus five new analogs, by kinetic and equilibrium measurements on complexes with the vesamicol receptor (VR) revealed nine analogs that are significantly more potent than vesamicol. Equilibrium measurements were performed at very low protein concentrations and extended incubation times, which allowed the characterization of very high affinity analogs. Better understanding of the structural binding requirements of the VR has resulted, and a spatial map of allowed hydrophobicity has been clearly established. Three analogs were resolved, and they displayed enantioselectivity ratios as high as 260 for binding to the VR (10-times higher than that of vesamicol). The most potent analog, 4-aminobenzovesamicol (ABV), was synthesized in tritiated form and shown to dissociate from the VR with a half-life of about 14 hr at 20 degrees. The estimated dissociation constant is < or = 6.5 +/- 0.5 pM. By reciprocal kinetic experiments with vesamicol and ABV, coincidence of the two binding sites on vesicles was established. The high affinity and enantioselectivity of ABV and other similar analogs, coupled with good chemical and radiochemical stability, make these ligands attractive for the study of the VR in complex tissues. The observed difference between the equilibrium dissociation constant for the vesamicol-VR complex as estimated by titration with [3H]vesamicol (7.6 nM) and by displacement of subsaturating [3H]vesamicol by nonlabeled vesamicol (1.0 nM) suggests that high and low affinity populations of the VR exist.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8371715

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  6 in total

1.  The maximal affinity of ligands.

Authors:  I D Kuntz; K Chen; K A Sharp; P A Kollman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  Synthesis and in vitro biological evaluation of carbonyl group-containing inhibitors of vesicular acetylcholine transporter.

Authors:  Simon M N Efange; Anil B Khare; Krystyna von Hohenberg; Robert H Mach; Stanley M Parsons; Zhude Tu
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

3.  Synthesis and biological characterization of a promising F-18 PET tracer for vesicular acetylcholine transporter.

Authors:  Zhude Tu; Xiang Zhang; Hongjun Jin; Xuyi Yue; Prashanth K Padakanti; Lihai Yu; Hui Liu; Hubert P Flores; Kota Kaneshige; Stanley M Parsons; Joel S Perlmutter
Journal:  Bioorg Med Chem       Date:  2015-06-05       Impact factor: 3.641

4.  Search for the acetylcholine and vesamicol binding sites in vesicular acetylcholine transporter: the region around the lumenal end of the transport channel.

Authors:  Parul Khare; Anuprao Mulakaluri; Stanley M Parsons
Journal:  J Neurochem       Date:  2010-10-12       Impact factor: 5.372

5.  Synthesis and in vitro and in vivo evaluation of 18F-labeled positron emission tomography (PET) ligands for imaging the vesicular acetylcholine transporter.

Authors:  Zhude Tu; Simon M N Efange; Jinbin Xu; Shihong Li; Lynne A Jones; Stanley M Parsons; Robert H Mach
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

6.  Multiple protonation states of vesicular acetylcholine transporter detected by binding of [3H]vesamicol.

Authors:  Parul Khare; Aubrey R White; Stanley M Parsons
Journal:  Biochemistry       Date:  2009-09-29       Impact factor: 3.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.